Dyadic collaborates with leading global animal health companies to demonstrate its C1 platform to treat farm animal diseases

Dyadic International Inc (NASDAQ:DYAI) has entered into fully funded collaborations with two of the leading global animal health companies to demonstrate its proprietary C1 platform for expression and production of therapeutic proteins for companion and farm animal diseases. "We are very pleased to announce two new animal health-related research agreements with global leaders,” Dyadic CEO Mark Emalfarb said in a statement Wednesday. “Our efforts in animal health reinforce our highly targeted business development approach to large and growing global markets.” READ: Dyadic and Frederick National Laboratory to develop C1 cell lines for coronavirus vaccine candidates Emalfarb noted that the regulatory pathway in animal health is much shorter with the cost of goods, being a much more critical issue when compared to human vaccines and drugs.  “We believe our C1 technology platform is well-positioned to enable our collaborators to bring more products to market, help speed commercialization, deliver larger quantities at lower cost and be manufactured at flexible commercial scales, to improve animal health,” he said. "In addition, these new collaborations, combined with our COVID-19 efforts with the Frederick National Laboratory announced on June 10th, highlight our significant momentum and progress in both animal and human health as well the broad application potential of our C1 technology platform.”  Emalfarb also noted that during the past six months, Dyadic has announced three fully funded animal health research collaborations and is now working with all four leading animal health care companies.  Dyadic, based in Jupiter, Florida, said its C1 gene expression technology may help get biologic vaccines, drugs and other biologic products to market faster, in greater volumes and at lower cost.  Contact the author: patrick@proactiveinvestors.com Follow him on Twitter @PatrickMGraham